SCHEMBL6725970

SCHEMBL6725970

Cc1cc(-c2ccc(C(=O)N3CCN(S(=O)(=O)[N+]4([O-])Cc5ccc(Cl)cc5C4)CC3)cc2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 4/20 0.42
SLC6A3 Q01959 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
LSS P48449 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
F10 P00742 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
STAT3 P40763 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6725899 0.83 POLB (0.42) MAPKAPK2F10MEN1KMT2ASMN1; SMN2
SCHEMBL6726361 0.83 MAPT (0.35) F10KMT2AMAPTMAPK1SMN1; SMN2
SCHEMBL6730095 0.82 SLC6A7 (0.47) SLC6A7SLC6A3MAPKAPK2LSSPSEN1
SCHEMBL6195975 0.78 F10 (0.57) F10SMN1; SMN2
Hydrochloric Acid SCHEMBL6195328 0.78 F10 (0.56) F10SMN1; SMN2
SCHEMBL6732187 0.75 PAK4 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6737185 0.74 F10 (0.68) F10KLK1
SCHEMBL6731390 0.73 F10 (0.49) SLC6A7SLC6A3MAPKAPK2F10MEN1
SCHEMBL6731383 0.73 F10 (0.49) SLC6A7SLC6A3MAPKAPK2F10MEN1
SCHEMBL6730433 0.70 LSS (0.54) SLC6A7SLC6A3LSSF10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 SLC6A7 4827/4885SLC6A3 3041/4885MAPKAPK2 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.